The protective effects of nanocurcumin against unpleasant effects of radiotherapy
Not Applicable
- Conditions
- Tyroid cancer.Malignant neoplasm of thyroid gland
- Registration Number
- IRCT2016030917006N2
- Lead Sponsor
- Vice chancellor for research, Mashhad University of Medical Sciences. (Primary sponsor)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 90
Inclusion Criteria
age between 18 to 65; patients with papillary or follicular thyroid cancer; Desire to join to study
Exclusion criteria: previous history of radioiodine therapy; history of head and neck radiotherapy; previous history of thyroid surgery; pregnancy; lactation; history of chronic rheumatologic disease; history of LASIK or PRK on eye or surgery of salivary glands; PT less than normal
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Presence/severity of mucositis. Timepoint: first and third week post drug administration. Method of measurement: observation, physical examination, laboratory assessment.;Changes in taste. Timepoint: one and three weeks post radioiodine therapy. Method of measurement: observation, physical examination.;Xerestomia. Timepoint: one and three weeks post radioiodine therapy. Method of measurement: observation, physical examination.
- Secondary Outcome Measures
Name Time Method Blood cell count. Timepoint: two and twelve months post radioiodine therapy. Method of measurement: Laboratory test.;Tumour recurrence (local or distant). Timepoint: one year post radioiodine therapy. Method of measurement: Pysical examination, Lab results, Ultra sonography, Whole body iodine scan.